Novel Aldo-Keto Reductase 1C3 Inhibitor Affects Androgen Metabolism but Not Ovarian Function in Healthy Women: A Phase 1 Study
June 2023
in “
European Journal of Endocrinology
”
Studysummary This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on pmc.ncbi.nlm.nih.gov →